Changes in the Cytokine Profiles of Patients with Chronic Hepatitis B during Antiviral Therapy.

Ming Hui LI; Hui Hui LU; Qi Qi CHEN; Yan Jie LIN; Zhan ZENG; Yao LU; Lu ZHANG; Jian Ping DONG; Wei YI; Yao XIE

Return

Changes in the Cytokine Profiles of Patients with Chronic Hepatitis B during Antiviral Therapy.

Author: Ming Hui LI ^{1
,

2} ; Hui Hui LU ³ ; Qi Qi CHEN ² ; Yan Jie LIN ² ; Zhan ZENG ² ; Yao LU ³ ; Lu ZHANG ³ ; Jian Ping DONG ⁴ ; Wei YI ⁵ ; Yao XIE ^{1
,

2}
Author Information

1. Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
2. Department of Hepatology Division 2, Peking University Ditan Teaching Hospital, Beijing 100015, China.
3. Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
4. Department of Infectious Diseases, Haidian Hospital, Beijing Haidian Section of Peking University Third Hospital, Beijing 100080, China.
5. Department of Gynecology and Obstetrics, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Publication Type:Journal Article
Keywords: Chronic hepatitis B; Cytokine; Interferon; Nucleoside (nucleotide) analog
MeSH: Adult; Antiviral Agents/therapeutic use*; Cytokines/blood*; Female; Guanine/therapeutic use*; Hepatitis B, Chronic/drug therapy*; Humans; Interferon-alpha/therapeutic use*; Male; Polyethylene Glycols/therapeutic use*; Prospective Studies; Recombinant Proteins/therapeutic use*
From: Biomedical and Environmental Sciences 2021;34(6):443-453
CountryChina
Language:English
Abstract: Objective:To investigate the changes in the cytokine profiles of chronic hepatitis B (CHB) patients undergoing antiviral treatment.
Methods:Hepatitis B e antigen (HBeAg)-positive patients were treated with Pegylated interferon (PEG-IFN) and entecavir (ETV). Clinical biochemistry and cytokines were detected at baseline and every 3 months.
Results:In all, 200 patients completed 48 weeks of treatment, 100 in the PEG-IFN group and 100 in the ETV group. During 3-6 months of treatment, compared with baseline, the PEG-IFN group showed a significant decrease in interferon-gamma (IFN-γ), interleukin-17A (IL-17A), interleukin-6(IL-6), interleukin-10(IL-10), and transforming growth factor beta (TGF-β) (
Conclusion:During antiviral therapy, a change in the cytokine profile occurred; in the aspect of immune control and functional cure, PEG-IFN was significantly better than ETV.